Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senators Durbin, Hatch To Work Together On AER Plan

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement industry critic Sen. Richard Durbin (D-Ill.) will work alongside congressional industry supporters to develop legislation to create a mandatory serious adverse event reporting system
Advertisement

Related Content

Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements
Adverse Events Reporting Bill Approaching Consensus, Slated For Spring
Trade Groups Make AER Legislation Wish List; Preemption Is Top Priority
“Solid” GMPs Will Give FDA Adequate Supplement Enforcement – Crawford
FDA Dietary Supplement AER Detection, Analysis Need Refining – ASCPT
Durbin/Hatch bill
Senate Approps Committee CAERS About Supplement Adverse Events
Cannon Backs FSA Supplement Coverage; NNFA Urges Public Involvement
Rep. Pallone Introduces DSHEA Implementation Companion Bill
Supplements Containing Stimulants Would Need Preapproval Under Durbin Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS096999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel